Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease (extension study)
2018-002210-12Phase 3Unknown
- Sponsor
- Idorsia
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lucerastat in Fabry disease (FD), sponsored by Idorsia. Primary endpoint: Treatment-emergent adverse events and serious adverse events up to follow-up 1 visit. Status: unknown.
02
Drugs
lucerastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2018-002210-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002210-12.